linjc16/ctgov huggingface dataset:
Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH

Study Overview
=================
Brief Summary
-----------------
Several stimulation protocols have been used in in vitro fertilization (IVF) in a cycle of egg donation; recombinant FSH and human FSH are included. The effect of each kind of hormone on aneuploidy rate it is unknown. If there was an increase on aneuploidy rate of one of these stimulation protocols, there will be a negative effect on the successful rates in the egg donation cycles. The aim of this study is to observe if there is a different in aneuploidy rate and morphological oocyte parameters between different stimulation protocols.

Official Title
-----------------
Aneuploidy Rate Impact in Oocyte From Egg Donation Cycle With Different Stimulation Protocol: Recombinant FSH vs Human FSH

Conditions
-----------------
Aneuploidy Rate

Intervention / Treatment
-----------------
* Procedure: Stimulation with human FSH
* Procedure: Stimulation with recombinant FSH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egg donation cycles with more than 8MII in oocyte retrieval day Exclusion Criteria: Male factor Uterine malformations genetic alterations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Human FSH<br> | Procedure: Stimulation with human FSH<br>* Human FSH<br>|
| Active Comparator: Recombinant FSH<br> | Procedure: Stimulation with recombinant FSH<br>* Recombinant FSH<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneuploidy Rate | Analysis of all nuclei fixed | 2011 January | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oocyte morphology | Analysis of all oocytes | 2011 january | 
| Outcome rates (implantation, pregnancy and miscarriage rate) | Time requierd to know all the implantation, pregnancy and miscarriage rate | 2011 April |
Effects of Intensified Sodium Management in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study is to investigate whether intensive sodium management by dietary sodium restriction and by preventing positive sodium balance during dialysis can be successfully applied in chronic hemodialysis patients. Secondary aims are to test if sodium restriction has positive effects on the frequency of hospital admissions, blood pressure, fluid overload, quality of life and residual renal function.

Official Title
-----------------
A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.

Conditions
-----------------
Renal Failure Chronic Requiring Hemodialysis

Intervention / Treatment
-----------------
* Other: intensive sodium management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory, clinically stable maintenance hemodialysis patients on a thrice weekly HD regimen. Willing and able to provide written, signed informed consent after the nature of the study has been explained. Willing and able to comply with all study procedures. Age ≥18 years. Exclusion Criteria: Simultaneous participation in another clinical study except observational trials. Any psychological condition which could interfere with the patient's ability to comply with the study protocol. Pregnancy. Amputation of a limb. Pacemaker, implantable pump, artificial joint. Expectation that native kidney function will recover. Unable to verbally communicate in English or Spanish. Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center within the next 14 months. Life expectancy < 15 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intensive sodium management<br> | Other: intensive sodium management<br>* dietary sodium restriction avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms<br>|
| No Intervention: standard care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| feasibility of intensive sodium management |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospitalization |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sodium, hypertension, volume overload
Antiplatelet Effects in Stroke-Patients

Study Overview
=================
Brief Summary
-----------------
Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates with increased age. Most of patients rely on analgesic medication to control the pain. Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and South America, largely due to its favorable analgesic and antipyretic effects in conjunction with a low incidence of gastrointestinal complications when compared to other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However, it is known that there are substantial inter-individual response variabilities to antiplatelet medication. Furthermore, patients with impaired response to aspirin have a significant higher risk of recurrent cerebrovascular events. The investigators have recently shown that co-medication with aspirin and dipyrone in patients with coronary artery disease lead to insufficient antiplatelet effects of aspirin. The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in this study the investigators aim to examine, if co-medication of aspirin and dipyrone interaction also occurs in patients after ischemic stroke.

Official Title
-----------------
Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients

Conditions
-----------------
Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without analgesic comedication Exclusion Criteria: Reanimation cardiogenic shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac and cerebrovascular events (MACCE Events) during hospital stay |  | participants are followed until discharge up to 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aspirin, ischemic stroke, Antiplatelet Effects, metamizole, dipyrone
Calcium Electroporation for the Treatment of Keloids

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of calcium electroporation on keloids.

Detailed Description
-----------------
The keloids wil be treated with intratumoral injection of calcium followed by electroporation. It is a once only treatment and the patients will be followed up for 24 months.

Official Title
-----------------
Calcium Electroporation for the Treatment of Keloids

Conditions
-----------------
Keloid

Intervention / Treatment
-----------------
* Drug: Calcium chloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 1 keloid available to electroporation. Patient should have been offered standard treatment. At least 8 weeks since other keloid treatment. Performance status <2 (ECOG). Platelet count >50 mia/l International Normalized Ratio (INR) <1,2. Age >18. Patient should be able to understand participants information. Signed, informed consent. Exclusion Criteria: Clinically significant coagulopathy. Pregnancy or lactation. Participation in other clinical trial involving experimental drugs or participation in a clinical trial within 4 weeks before study treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Calcium electroporation<br>The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment. Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume. | Drug: Calcium chloride<br> <br> * Other names: EV substance codeSUB12664MIG;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response evaluated by Vancouver Scar Scale | Vancouver scar scale evaluate the keloids by: pigmentation, pliability, height, and vascularity. | After 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events to calcium electroporation. | Describe adverse events using Common Terminology for Adverse Events, version 4.0 | After 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Calcium electroporation, calcium, electroporation, electrotransfer, keloid
Motor REHAbilitation TEChnologies for CHIldren With Disability: A Cross-European Survey

Study Overview
=================
Brief Summary
-----------------
The aim of the RehaTech4Child survey led by EACD is to identify the digital technologies (e.g., robotic devices and treadmill systems, virtual reality and gaming systems, telehealth) that are used in clinical practices throughout Europe, and to know more about how rehabilitation professionals use or not use digital technologies in motor rehabilitation practices within the paediatric population. This knowledge would eventually help in designing the future technological developments based on the feedback from rehabilitation professionals.

Official Title
-----------------
Motor REHAbilitation TEChnologies for CHIldren With Disability

Conditions
-----------------
Children With Disabilities; Motor Rehabilitation; Technologies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rehabilitation professionals who use or not technologies in pediatric motor rehabilitation Practice in Europe Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Access, frequency of use and intention to use of digital technologies by paediatric motor rehabilitation professionals A Cross-European Web survey | To investigate the access to, the frequency of use and the intention to use digital technologies by paediatric motor rehabilitation professionals, and to assess their determinants | From Februray till June 2022 |
Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a multimedia educational computer program can increase colorectal cancer screening rates in low and adequate literacy patients.

Detailed Description
-----------------
Results will be stratified by low/marginal and adequate literacy as determined by the Rapid Estimate of Adult Literacy in Medicine instrument.

Official Title
-----------------
Overcoming Literacy Barriers in Colorectal Cancer Screening

Conditions
-----------------
Colorectal Cancer, Health Literacy

Intervention / Treatment
-----------------
* Behavioral: CHOICE decision aid
* Behavioral: YourMeds patient education program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English-speaking Scheduled to see an internal medicine provider No recent colorectal cancer screening Exclusion Criteria: Personal history of colorectal cancer Family history of colorectal cancer Blood seen in stools within last month Obvious cognitive or physical impairment that would prevent participation

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br> | Behavioral: CHOICE decision aid<br>* computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit<br>* Other names: CHOICE;|
| Placebo Comparator: Placebo group<br> | Behavioral: YourMeds patient education program<br>* computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit<br>* Other names: YourMeds;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Receipt of colorectal cancer screening |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in participants' readiness to be screened (Stage of Change) |  | Day 1 | 
| Self-reported intent to discuss colorectal cancer screening with healthcare provider |  | Day 1 | 
| Provider ordering a colorectal cancer screening test |  | Day 1 | 
| Participant completion of computer program without assistance |  | Day 1 | 
| Participant acceptance of computer program |  | Day 1 | 
| Number of polyps and cancers found by screening tests performed |  | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal cancer, Screening, Health literacy, Patient education, Computer assisted instruction
Trans-Rectal Ultrasound-Guided (TRUS) Adverse Events

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to identify any side effects caused by the implanting of markers via the rectum. The investigators will also try to determine if any other factors (such as the position of the markers) influence the risk of side effects. The study procedures consist of two questionnaires:The first will be completed immediately after the marker implantation and the second questionnaire will be completed during your radiotherapy planning.

Detailed Description
-----------------
Precise localisation of target organs has become increasingly important with the routine use of steep dose gradients from conformal and intensity modulated radiotherapy. This is particularly challenging when soft tissue target organs, such as the prostate, displace relative to bony anatomy. Although novel imaging techniques are being developed for the direct visualisation of such soft tissue structures, contrast and image quality is currently limited. However, the use of radio-opaque intra-prostatic fiducial markers(IPM) during high dose radiotherapy has proven very effective in terms of improving accuracy, and decreasing toxicity.

Official Title
-----------------
A Prospective Quantification of Patient-Reported Adverse Events Following Trans-Rectal Ultrasound-Guided Intra-Prostatic Marker Insertion

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have biopsy confirmed prostate cancer (any risk category) Have 3 intra-prostatic markers inserted at PMH prior to radiotherapy Be willing to provide written informed consent Be willing to complete the adverse event questionnaires

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prostate Cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantify adverse events reported by prostate patients following trans-rectal ultrasound-guided implantation of intra-prostatic markers for RT |  | 1.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intra-Prostate Markers, Transrectal Ultrasound, Prostate Cancer Patients
A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

Study Overview
=================
Brief Summary
-----------------
A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis

Detailed Description
-----------------
This is a clinical research study that will determine if there is a reduction in the signs and symptoms (such as back pain and stiffness) of patients with ankylosing spondylitis with infliximab therapy. This study will also study the safety of infliximab in patients with ankylosing spondylitis. The effect of infliximab on physical function, damage to joints and the quality of life in patients with ankylosing spondylitis will also be studied. Subjects received infusions of either placebo at weeks 0, 2, 6, 12, 18 and 5 mg/kg infliximab at weeks 24, 26, 30 and every 6 weeks through week 96, or 5 mg/kg infliximab at weeks 1, 2, 6, 12, 18 and every 6 weeks through week 96

Official Title
-----------------
A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy

Conditions
-----------------
Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Drug: infliximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have had a diagnosis of definite Akylosing Spondylitis for at least 3 months prior to screening Have active disease with spinal pain receiving or intolerant to standard anti-inflammatory agents Exclusion Criteria: Have Rheumatoid Arthritis, systemic lupus erythematosus, or other inflammatory rheumatic disease Have a documented history of fibromyalgia Have total ankylosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: infliximab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint of this study was the proportion of subjects who achieved an ASAS 20 response at week 24. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change from baseline in BASFI at week 24, the proportion of subjects who achieved an AS major clinical response at week 24, and the change from baseline in the physical component summary score of the SF-36 at week 24 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ankylosing Spondylitis, infusion